Trial Profile
Incidence rate, risk factors, and final outcomes of patients with age-related macular degeneration (AMD) who have experienced vision loss during aflibercept treatment.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Jan 2018
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- 22 Jan 2018 New trial record